Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The form provides key information about the dealings of the exempt principal trader with recognized intermediary status. The form states that Panmure Gordon (UK) Limited made purchases of 25,000 securities of Allergy Therapeutics plc at a price of 0.027 per unit. However, there were no sales of securities by the exempt principal trader. The form does not mention any cash-settled derivative transactions or stock-settled derivative transactions. Additionally, there are no indemnity or option arrangements, agreements, arrangements, or understandings relating to relevant securities mentioned in the form. The disclosure was made on September 5, 2023, and the contact person for further information is Freddie Wooding at +44 (0)20 7886 2969.